Chi-Med's Crohn's disease therapy shows positive trend in Phase II
This article was originally published in Scrip
Executive Summary
The Chi-Med company Hutchison MediPharma has reported preliminary results from a placebo-controlled Phase II trial with HMPL-004, its plant-derived therapy for Crohn's disease, showing a trend towards efficacy.